查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1986883

反义和RNAi疗法市场规模、份额、趋势和预测：按技术、给药途径、应用和地区划分，2026-2034年

Antisense & RNAi Therapeutics Market Size, Share, Trends and Forecast by Technology, Route of Administration, Application, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

2025年全球反义和RNAi疗法市场规模为19.1亿美元。展望未来，IMARC集团预测该市场将在2026年至2034年间以6.74%的复合年增长率成长，到2034年达到34.3亿美元。目前，北美市场主导地位，预计2025年将占40%的市场。该地区拥有许多优势，例如先进的生物技术基础设施、大量的公共和私人研究投资、有利于快速核准治疗方法的法规环境，以及较高的遗传疾病患病率，所有这些因素都促进了反义和RNAi疗法市场份额的增长。

受多种强劲因素的推动，全球反义寡核苷酸和RNAi疗法市场正经历着蓬勃发展。遗传性疾病、代谢性疾病和慢性疾病在全球范围内的发病率不断上升，使得针对基因静默疗法的需求空前高涨，这些疗法旨在解决疾病的根本分子机制，而不仅仅是缓解症状。寡核苷酸化学的进步，特别是硫代磷酸酯骨架的引入和化学修饰，显着提高了药物的稳定性、特异性和生物利用度。对RNA生物学更深入的科学理解，拓展了以往难以治疗疾病的治疗选择。全球对生物製药研发的投资正在加速新型治疗标靶的发现。越来越多的临床试验正在研究反义寡核苷酸和RNAi平台在多种适应症中的应用，从而扩大了其应用范围。基因组分析技术推动的个人化医疗转型，也为患者量身定制治疗方案创造了机会，这预示着反义寡核苷酸和RNAi治疗方法市场在这个专业化且快速发展的领域拥有光明的前景。

由于多种因素，美国正崛起为反义和RNAi疗法市场的领先地区。美国拥有世界一流的生物技术公司、学术研究机构和政府资助计画组成的紧密网络，这些机构携手合作，共同推动基于RNA的疗法的发现。美国食品药物管理局（FDA）管理的健全法规结构，透过快速通道、突破性疗法认定和加速核准等加速途径，积极支持创新，从而加速寡核苷酸候选化合物的临床应用。患者的高度认知和参与临床试验的意愿，也为罕见遗传疾病、神经退化性疾病和肿瘤适应症的研发提供了支持。 2025年，RNAi疗法领域的领导企业Alnylam Pharmaceuticals, Inc.宣布计划扩建其位于麻萨诸塞州诺顿的先进製造厂。该公司计划投资2.5亿美元，建造业内首个专门用于siRNA酶连接生产的专用设施。这项投资有望大幅提高产能并大幅降低製造成本，使 Alnilam 能够支持其不断扩大的新型疗法产品线中未来的产品上市。

反义和RNAi疗法的市场趋势：

药物输送系统的技术进步

药物递送技术的快速发展是此治疗领域的关键驱动力。脂质体奈米颗粒正逐渐成为将短干扰RNA（siRNA）和反义寡核苷酸递送至目标细胞的黄金标准，可提高细胞内摄取并减少核酸酶降解。 GalNAc-siRNA偶联平台彻底革新了肝臟标靶化，与传统製剂相比，能够以显着较低的剂量将药物精准递送至肝细胞。这些创新提高了RNA类药物的治疗指数，并实现了皮下给药方案，从而增强了患者的依从性。诸如硫代磷酸酯结合、2'-O-甲基化和锁核酸（LNA）基序等先进的化学修饰进一步延长了寡核苷酸疗法的半衰期并提高了其效力。 2025年的研究重点将日益集中于拓展递送系统，使其能够到达肝臟以外的肌肉组织、中枢神经系统和肺细胞。人工智慧正被整合到寡核苷酸序列的设计中，以提高标靶选择性并最大限度地减少脱靶效应。

遗传性疾病和慢性病盛行率增加

全球遗传性疾病、罕见疾病和慢性病负担日益加重，显着推动了反义寡核苷酸和RNA干扰疗法市场的成长。亨廷顿舞蹈症、遗传性转甲状腺素类淀粉沉积症样变性、脊髓性肌肉萎缩症以及多种遗传性癌症等疾病缺乏有效的传统药物治疗方法方法，因此对基于核酸的基因静默疗法的需求持续旺盛。反义寡核苷酸和RNA干扰平台透过在mRNA层级选择性地定序致病基因，为治疗提供了独特的优势，从而能够针对异常蛋白质表现引起的疾病进行标靶干预。全球人口老化加剧，导致与老龄化相关的遗传性和退化性疾病的盛行率上升，扩大了符合这些治疗方法适用人群的范围。根据美国国立卫生研究院（NIH）统计，目前已发现7,000多种罕见疾病，其中约80%为遗传性疾病，影响全球约3亿人口。这种巨大的未满足需求持续推动着强大的研发投资和强劲的研发管线扩张，反映了全球多个治疗适应症的反义和 RNAi 疗法市场的趋势。

新治疗方法的有利监管条件

全球范围内有利的法规环境是推动反义寡核苷酸和RNA干扰疗法市场成长的关键因素。包括美国食品药物管理局（FDA）和欧洲药品管理局（EMA）在内的监管机构正在实施专门机制，以加速新型核酸疗法的研发和核准。孤儿药认定、突破性治疗方法认定、快速核准和优先审评券等倡议，为企业投资反义寡核苷酸和RNA干扰疗法的研发提供了切实有效的奖励，尤其是在罕见疾病和医疗需求尚未得到充分满足的疾病领域。这些认定缩短了研发时间和相关成本，使中小型生物技术公司能够与大型製药企业公平竞争。加速核准流程正在加快该领域的核准速度，并增强商业性对这些治疗方法的信心。 2025年3月，美国FDA核准了Qfitlia（fitusiran），这是一种用于治疗A型和B型血友病的皮下siRNA疗法。这是Alnilam公司研发的第六种获美国市场核准的RNAi药物，显示监管审批流程正在加速推进。这项突破性进展进一步增强了投资者对反义和RNAi疗法领域长期潜力的信心。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 二手资讯
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章：引言

第五章：全球反义与RNAi治疗市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依技术划分

  • RNA干扰
    • 主要部分
      • siRNA
      • miRNA
  • 反义RNA

第七章 市场区隔：依给药途径

  • 静脉注射
  • 皮下注射
  • 鞘内给药
  • 肺部给药
  • 腹腔注射
  • 其他的

第八章 市场区隔：依应用领域划分

  • 肿瘤学
  • 心血管疾病（CVD）
  • 呼吸系统疾病
  • 肾臟疾病
  • 神经退化性疾病
  • 遗传性疾病
  • 感染疾病
  • 其他的

第九章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Alnylam Pharmaceuticals Inc.
    • Arbutus Biopharma Corporation
    • Arrowhead Pharmaceuticals Inc.
    • Benitec Biopharma Ltd.
    • Bio-Path Holdings Inc.
    • Dicerna Pharmaceuticals Inc.（Novo Nordisk A/S）
    • Ionis Pharmaceuticals Inc.
    • OliX Pharmaceuticals Inc.
    • Phio Pharmaceuticals Corp.
    • Sarepta Therapeutics Inc.
    • Silence Therapeutics
    • Sirnaomics Inc.
Product Code: SR112026A6549

The global antisense & RNAi therapeuticmarket size was valued at USD 1.91 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 3.43 Billion by 2034, exhibiting a CAGR of 6.74% from 2026-2034. North America currently dominates the market, holding a market share of 40% in 2025. The region benefits from advanced biotechnology infrastructure, significant public and private research investment, a favorable regulatory environment enabling expedited therapy approvals, and high prevalence of genetic disorders among the population, all contributing to the antisense & RNAi therapeutics market share.

The global antisense & RNAi therapeutics market is experiencing robust expansion driven by several compelling factors. The rising global incidence of genetic, metabolic, and chronic diseases is generating unprecedented demand for targeted gene-silencing therapies that address molecular root causes rather than symptoms. Advancements in oligonucleotide chemistry, particularly the introduction of phosphorothioate backbones and chemical modifications, have significantly enhanced drug stability, specificity, and bioavailability. Growing scientific understanding of RNA biology is expanding the therapeutic landscape to previously untreatable conditions. Global investments in biopharmaceutical research and development are accelerating the identification of novel therapeutic targets. The ongoing proliferation of clinical trials investigating antisense oligonucleotide and RNAi platforms across multiple indications is broadening their applicability. The shift toward personalized medicine, driven by genomic profiling technologies, is also creating tailored treatment opportunities, reflecting positive antisense & RNAi therapeutics market outlook for this specialized and rapidly advancing modality.

The United States has emerged as a major region in the antisense & RNAi therapeutics market owing to many factors. The country hosts a dense network of world-class biotechnology companies, academic research institutions, and government-funded programs that collectively advance RNA-based therapeutic discovery. A robust regulatory framework administered by the FDA actively supports innovation through expedited pathways including Fast Track, Breakthrough Therapy Designation, and Accelerated Approval, enabling quicker clinical translation of oligonucleotide candidates. High patient awareness and participation in clinical trials supports pipeline development across rare genetic, neurodegenerative, and oncological indications. In 2025, Alnylam Pharmaceuticals, Inc., a top company in RNAi therapeutics, revealed its intention to expand its advanced manufacturing plant located in Norton, Massachusetts. The Company is set to invest $250 million to develop what is expected to be the industry's first fully dedicated, proprietary facility for siRNA enzymatic-ligation manufacturing. This investment is anticipated to greatly increase capacity, considerably lower production costs, and enable Alnylam to assist future launches within its expanding pipeline of possible new treatments

ANTISENSE & RNAI THERAPEUTICS MARKET TRENDS:

Technological Advancements in Drug Delivery Systems

The rapid evolution of drug delivery technologies is a key factor propelling this therapeutic field. Lipid nanoparticles have emerged as the gold standard for delivering short interfering RNA and antisense oligonucleotides into target cells, improving cellular uptake and reducing nuclease-mediated degradation. GalNAc-siRNA conjugate platforms have revolutionized hepatic targeting, enabling precise delivery to liver cells at substantially lower doses compared to earlier formulations. These innovations have improved the therapeutic index of RNA-based medicines, enabling subcutaneous administration regimens that enhance patient compliance. Advanced chemical modifications including phosphorothioate linkages, 2'-O-methyl groups, and locked nucleic acid motifs have further extended the half-life and potency of oligonucleotide therapeutics. Research efforts in 2025 are increasingly focused on expanding delivery systems beyond the liver to reach muscle tissue, the central nervous system, and lung cells. Artificial intelligence is being integrated into oligonucleotide sequence design to improve target selectivity and minimize off-target effects.

Rising Prevalence of Genetic and Chronic Diseases

The escalating global burden of genetic, rare, and chronic diseases is significantly supporting the antisense & RNAi therapeutics market growth. Conditions such as Huntington's disease, hereditary transthyretin amyloidosis, spinal muscular atrophy, and various hereditary cancers lack effective treatments using conventional pharmaceutical approaches, creating sustained demand for nucleic acid-based gene-silencing therapies. Antisense oligonucleotides and RNAi platforms offer a unique therapeutic advantage by selectively silencing disease-causing genes at the mRNA level, providing targeted intervention for conditions driven by aberrant protein expression. The growing aging global population is amplifying the prevalence of age-related genetic and degenerative disorders, expanding the addressable patient base for these therapeutics. According to the National Institutes of Health (NIH), over 7,000 rare diseases have been identified, with approximately 80% having a genetic origin, collectively affecting an estimated 300 million people worldwide. This enormous unmet medical need continues to generate strong research investments and robust pipeline expansion, reflecting growing antisense & RNAi therapeutics market trends across multiple therapeutic indications globally.

Favorable Regulatory Landscape for Novel Therapies

The supportive global regulatory environment represents a significant enabler of the antisense & RNAi therapeutics market forecast. Regulatory agencies including the FDA in the United States and the European Medicines Agency have implemented specialized mechanisms to accelerate the development and approval of novel nucleic acid therapeutics. Programs such as Orphan Drug Designation, Breakthrough Therapy Designation, Fast Track approval, and Priority Review vouchers provide meaningful incentives for companies to invest in antisense and RNAi development, particularly for rare and underserved disease areas. These designations reduce development timelines and associated costs, enabling smaller biotechnology firms to compete effectively alongside large pharmaceutical organizations. Accelerated pathways have facilitated a steady stream of approvals in this class, reinforcing commercial confidence in these modalities. In March 2025, the U.S. FDA approved Qfitlia (fitusiran), a subcutaneous siRNA therapeutic for hemophilia A or B, marking the sixth Alnylam-discovered RNAi medicine to receive U.S. market clearance and demonstrating the accelerating pace of regulatory advancement. This milestone reinforces investor confidence in the Antisense & RNAi Therapeutics sector's long-term potential.

ANTISENSE & RNAI THERAPEUTICS INDUSTRY SEGMENTATION:

Analysis by Technology:

  • RNA Interference
    • siRNA
    • miRNA
  • Antisense RNA

RNA Interference holds 60% of the market share. RNA interference operates through small interfering RNA (siRNA) and microRNA (miRNA) molecules that engage the RNA-induced silencing complex (RISC) to achieve targeted gene silencing at the post-transcriptional level. This mechanism provides unparalleled precision in suppressing disease-causing gene expression, making it particularly effective for conditions where a specific pathogenic protein must be inhibited. The siRNA pathway has been the basis for several FDA-approved medicines, demonstrating proven clinical efficacy across hepatic, hematological, and neurological indications. Key advantages of RNAi over antisense approaches include greater potency at lower doses and catalytic activity within the RISC complex, enabling repeated cycles of gene silencing. Ongoing research into extra-hepatic delivery is expected to unlock new application areas including neurology, oncology, and muscle diseases, further solidifying the dominant position of RNA interference within this expanding market.

Analysis by Route of Administration:

  • Intravenous Route
  • Subcutaneous Route
  • Intrathecal Route
  • Pulmonary Delivery
  • Intraperitoneal Injection
  • Others

Intravenous Route leads the market with a share of 26%. The intravenous route enables systemic delivery of antisense oligonucleotides and RNAi therapeutics, facilitating rapid distribution throughout the bloodstream for conditions requiring broad biodistribution. Intravenous administration is particularly relevant for oncological and hematological applications where systemic circulation is essential for reaching tumor cells and blood-borne targets. Lipid nanoparticle-encapsulated RNAi therapeutics such as patisiran, the first FDA-approved siRNA drug, were initially formulated for intravenous delivery, establishing a strong clinical precedent for this administration route. The well-established hospital infusion infrastructure globally supports broad adoption of intravenous RNA therapeutics in developed healthcare markets. This route remains essential for the clinical management of conditions requiring rapid therapeutic effect or systemic distribution. Although newer formulations are transitioning toward subcutaneous delivery for improved patient convenience, the intravenous route retains a significant and well-validated position across multiple RNA therapeutic indications globally.

Analysis by Application:

  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Renal Diseases
  • Neurodegenerative Disorders
  • Genetic Disorders
  • Infectious Diseases
  • Others

Oncology dominates the market, with a share of 31%. The application of antisense oligonucleotides and RNAi therapeutics in oncology represents one of the most dynamic and rapidly growing segments in this field. Cancer, by its nature, is driven by aberrant gene expression, making it an ideal candidate for nucleic acid-based gene-silencing approaches. RNAi and antisense technologies enable selective suppression of oncogenes, resistance pathways, and immune evasion mechanisms that drive tumor growth and survival. Multiple RNAi-based oncology programs are currently advancing through clinical development pipelines, targeting genes such as VEGF, kinesin spindle protein, and various tumor-specific mRNAs. The growing understanding of cancer genomics, driven by next-generation sequencing, is identifying novel targetable sequences for antisense and RNAi drug design. This persistent unmet need across solid and hematological cancers continues to propel the Antisense & RNAi Therapeutics sector's oncology-focused applications.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 40% of the share, enjoys the leading position in the market. The region's dominance is underpinned by exceptional biotechnology infrastructure, world-class academic research institutions, substantial public and private sector R&D investment, and a regulatory environment that actively facilitates the development and commercialization of novel nucleic acid therapeutics. The United States in particular is home to pioneering companies that led the development of the world's first approved antisense and RNAi medicines. High patient awareness, widespread reimbursement coverage, and strong healthcare spending collectively drive demand for advanced therapies across genetic, neurological, and cardiovascular indications. In 2025, variouspharmaceutical and biotechnology companies were actively working on antisense oligonucleotide programs in the United States, as reported by clinical pipeline analyses, highlighting the region's exceptional research density. Canada also contributes to regional growth through government-funded biotechnology initiatives and a growing base of RNA therapeutics startups, further reinforcing North America's leading regional position within the global landscape.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET ANALYSIS

The United States is the world's largest individual market for antisense & RNAi therapeutics, driven by a unique combination of scientific leadership, regulatory innovation, and healthcare infrastructure. The country's biotechnology ecosystem, centered in regions such as Greater Boston, the San Francisco Bay Area, and Research Triangle Park, houses the largest concentration of RNA therapeutics companies globally. The National Institutes of Health (NIH) continues to direct substantial funding toward foundational RNA biology and clinical translation research, supporting a robust pipeline of investigational oligonucleotide therapies. Favorable reimbursement policies for approved specialty therapeutics, including orphan drugs, enable broad commercial uptake of high-cost RNA medicines across patient populations. The FDA's commitment to novel therapy pathways, evidenced by multiple Breakthrough Therapy and Fast Track designations for antisense and RNAi candidates, significantly accelerates development timelines. In April 2025, the FDA granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide targeting tau protein, for Alzheimer's disease treatment, reflecting the agency's supportive stance toward advanced nucleic acid medicines. The country's large patient population with rare genetic disorders, neurological diseases, and oncological conditions continues to generate consistent demand for innovative gene-silencing therapies throughout the forecast period.

EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET ANALYSIS

Europe represents the second-largest region in the antisense & RNAi therapeutics market, supported by a mature pharmaceutical industry, strong academic research base, and harmonized regulatory frameworks coordinated by the European Medicines Agency. European countries including Germany, France, the United Kingdom, and Switzerland are home to internationally recognized biotechnology centers and academic institutions that actively contribute to RNA therapeutics innovation. The EMA has implemented favorable regulatory designations, including orphan medicine status and adaptive licensing pathways, to incentivize development of treatments for rare genetic diseases where antisense and RNAi approaches show strong promise. Reimbursement systems across major European markets support patient access to newly approved specialty therapies. High incidence of hereditary transthyretin amyloidosis, Duchenne muscular dystrophy, and rare genetic disorders in European patient populations continues to drive steady clinical demand.

ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET ANALYSIS

Asia-Pacific is the fastest-growing region in the antisense & RNAi therapeutics market, driven by rapidly expanding healthcare infrastructure, increasing biotechnology investment, and growing patient awareness of advanced gene-silencing therapies. Countries such as China, Japan, South Korea, and India are intensifying domestic research and development capabilities in nucleic acid therapeutics, with several local biotechnology companies pursuing RNAi-based programs. Government initiatives across the region are supporting the development of RNA-based precision medicines as part of broader national biotechnology strategies. According to the World Health Organization (WHO), Asia-Pacific was home to over 4.7 billion people as of 2024, representing one of the world's largest patient pools for rare, genetic, and chronic diseases requiring advanced therapeutic interventions. The expansion of clinical trial activity and growing regulatory harmonization with international standards are positioning Asia-Pacific as a key growth engine for the global Antisense & RNAi Therapeutics sector.

LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET ANALYSIS

Latin America represents an emerging growth opportunity in the antisense & RNAi therapeutics market, underpinned by a growing patient population, rising healthcare expenditure, and increasing government focus on advanced biopharmaceutical access. Brazil and Mexico lead regional activity, with expanding clinical trial participation and evolving regulatory frameworks being developed to accommodate novel genetic medicines. Growing awareness of rare disease management, supported by patient advocacy organizations and international pharmaceutical partnerships, is enhancing access to approved RNA therapeutics. Moreover, the heightened occurrence of new cancer diagnoses in 2024 is highlighting the significant unmet need for targeted oncology therapeutics including gene-silencing modalities and underscoring the region's long-term market potential.

MIDDLE EAST AND AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET ANALYSIS

The Middle East and Africa market for antisense & RNAi therapeutics is at an early development stage but exhibits meaningful long-term potential. Gulf Cooperation Council countries, particularly Saudi Arabia and the United Arab Emirates, are investing substantially in healthcare infrastructure modernization and advanced pharmaceutical access as part of national economic diversification strategies. Growing awareness of genetic diseases and rare conditions, combined with rising healthcare expenditure, is creating demand for specialized therapies. According to the World Health Organization (WHO), the Middle East and Africa region recorded a major number of new cancer cases in 2024, highlighting growing unmet therapeutic need and creating incremental opportunities for the adoption of innovative antisense and RNAi therapies across the region.

COMPETITIVE LANDSCAPE:

The antisense & RNAi therapeutics market is characterized by a dynamic competitive environment comprising established pharmaceutical leaders, dedicated RNA therapeutics companies, and innovative biotechnology entrants. Leading players maintain competitive positions through proprietary delivery platform technologies, extensive patent portfolios covering oligonucleotide chemistry and target sequences, and robust clinical pipelines spanning multiple disease indications. Strategic alliances between large pharmaceutical companies and specialized RNA biotechnology firms have become a defining feature of the competitive landscape, enabling shared expertise in drug development and commercialization. Companies are increasingly leveraging conjugate delivery technologies, particularly GalNAc-siRNA systems, to differentiate their product candidates through improved potency, selectivity, and dosing convenience. Manufacturing scale-up has emerged as a key competitive dimension, with major players investing in proprietary production platforms to reduce costs and support pipeline expansion. Ongoing competition for orphan drug designations and breakthrough therapy status provides an additional avenue for differentiation in this specialized and rapidly evolving market.

The report provides a comprehensive analysis of the competitive landscape in the antisense & RNAi therapeutics market with detailed profiles of all major companies, including:

  • Alnylam Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals Inc.
  • Benitec Biopharma Ltd.
  • Bio-Path Holdings Inc.
  • Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
  • Ionis Pharmaceuticals Inc.
  • OliX Pharmaceuticals Inc.
  • Phio Pharmaceuticals Corp.
  • Sarepta Therapeutics Inc.
  • Silence Therapeutics
  • Sirnaomics Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the antisense & RNAi therapeutics market?

2. What is the future outlook of the antisense & RNAi therapeutics market?

3. What are the key factors driving the antisense & RNAi therapeutics market?

4. Which region accounts for the largest antisense & RNAi therapeutics market share?

5. Which are the leading companies in the global antisense & RNAi therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antisense & RNAi Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 RNA Interference
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 siRNA
      • 6.1.2.2 miRNA
    • 6.1.3 Market Forecast
  • 6.2 Antisense RNA
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Intravenous Route
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Subcutaneous Route
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intrathecal Route
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pulmonary Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Intraperitoneal Injection
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cardiovascular Diseases (CVDs)
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Respiratory Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Renal Diseases
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Neurodegenerative Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Genetic Disorders
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Infectious Diseases
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast
  • 8.8 Others
    • 8.8.1 Market Trends
    • 8.8.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Alnylam Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Arbutus Biopharma Corporation
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Arrowhead Pharmaceuticals Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Benitec Biopharma Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Path Holdings Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ionis Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 OliX Pharmaceuticals Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Phio Pharmaceuticals Corp.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Sarepta Therapeutics Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Silence Therapeutics
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 Sirnaomics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Antisense & RNAi Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Antisense & RNAi Therapeutics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Antisense & RNAi Therapeutics Market: Breakup by Technology (in %), 2025
  • Figure 5: Global: Antisense & RNAi Therapeutics Market: Breakup by Route of Administration (in %), 2025
  • Figure 6: Global: Antisense & RNAi Therapeutics Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Antisense & RNAi Therapeutics Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Antisense & RNAi Therapeutics (RNA Interference) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Antisense & RNAi Therapeutics (RNA Interference) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Antisense & RNAi Therapeutics (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Antisense & RNAi Therapeutics (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Antisense & RNAi Therapeutics (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Antisense & RNAi Therapeutics (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: North America: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: North America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: United States: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: United States: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Canada: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Canada: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Asia-Pacific: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Asia-Pacific: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: China: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: China: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Japan: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Japan: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: India: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: India: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: South Korea: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: South Korea: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Australia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Australia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Indonesia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Indonesia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Europe: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Europe: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Germany: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Germany: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: France: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: France: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: United Kingdom: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: United Kingdom: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Italy: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Italy: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Spain: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Spain: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Russia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Russia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Latin America: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Latin America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Brazil: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Brazil: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Mexico: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Mexico: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Middle East and Africa: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Middle East and Africa: Antisense & RNAi Therapeutics Market: Breakup by Country (in %), 2025
  • Figure 88: Middle East and Africa: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Global: Antisense & RNAi Therapeutics Industry: SWOT Analysis
  • Figure 90: Global: Antisense & RNAi Therapeutics Industry: Value Chain Analysis
  • Figure 91: Global: Antisense & RNAi Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antisense & RNAi Therapeutics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 3: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 4: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Antisense & RNAi Therapeutics Market: Competitive Structure
  • Table 7: Global: Antisense & RNAi Therapeutics Market: Key Players